×
Customize
?
Start
Cancer Types
Quick Links
Events
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Prostate Cancer
Featured Content
Receiving a diagnosis of prostate cancer can be frightening and confusing. Understanding the details of your specific cancer and how they relate to your prognosis and treatment planning is an important first step toward shared decision-making between you and your physicians. In these CURE Connections programs you will learn the meaning of the PSA test, prostate cancer staging and grading, and how these factors are used to determine which treatment approach is right for you. Management of prostate cancer related symptoms, available treatments, and how to deal with side effects are also discussed. In addition, you will hear from patients and caregivers about their personal experiences with prostate cancer.
Gogs Gagnon
Conor Killmurray
The Food and Drug Administration’s approval of the PARP inhibitor Lynparza for patients with metastatic prostate cancer gives a smaller subgroup of patients another treatment option if hormonal therapies do not work.
Beth Fand Incollingo
The Food and Drug Administration gave the green light to the PARP inhibitor Lynparza for men with metastatic castration-resistant prostate cancer that has a defective DNA-repair process and has progressed after treatment with the novel hormone-controlling drugs Xtandi (enzalutamide) or Zytiga (abiraterone acetate).
Beth Fand Incollingo
The PARP inhibitor Rubraca represents a new treatment option for men with metastatic castration-resistant prostate cancer that expresses a BRCA gene mutation and has been previously treated with hormonal therapy and taxane-based chemotherapy.
Ryan McDonald
Obesity was associated with increased cardiovascular disease-related mortality and all-cause mortality, as well as potentially increased prostate cancer-specific mortality, in survivors of nonmetastatic prostate cancer.
Beth Fand Incollingo
The PARP inhibitor Lynparza improves survival and delays disease progression in men with metastatic castration-resistant prostate cancer that expresses certain gene mutations inhibiting DNA repair, a study shows.
Beth Fand Incollingo
An imaging technique known as PSMA PET/CT can detect disease spread at diagnosis more effectively than conventional scans, helping doctors to prescribe appropriate treatments.
Conor Killmurray
From an investigational cancer therapy being studied as a treatment for COVID-19 to the NBA and NHL helping to raise over $500,000 for prostate cancer research, here’s what’s making headlines in the cancer space this week.
Ryan McDonald
A medication that is commonly prescribed to treat depression appeared well tolerated in patients with biochemical recurrent prostate cancer.
Ryan McDonald
Patients with cancer who have routine follow up appointments are being asked to reschedule to help combat the spread of COVID-19.